GSK establish cell and gene therapy collaboration with Miltenyi Biotec
pharmafile | March 16, 2016 | News story | Medical Communications, Research and Development | GSK, GlaxoSmithKline, cell and gene therapy, collaboration, miltenyi biotec
GlaxoSmithKline (NYSE:GSK) has announced a strategic collaboration with Miltenyi Biotec that will see GSK’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s global leadership in cell processing and related technologies in cell therapy.
The partnership will see the two optimise the manufacture and delivery of these personalised therapies using increased automation and cutting edge processing technology.
This move further reinforces GSK’s emerging cell and gene therapy R&D platform to underpin development of novel therapies in oncology and rare diseases – two of its core research areas.
The goal of this collaboration is to use this increased automation to further industrialise cell and gene therapy processes. This could, in turn, reduce the costs and geographical barriers associated with this treatment approach, speed development of therapies and support their potential beyond rare diseases and limited populations.
The pair will also bring together the technology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics – cells that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. GSK and Miltenyi Biotec will collaborate on defined CAR-T oncology targets and on the development of advancements in technologies in this space, to complement GSK’s existing CAR-T preclinical portfolio.
Patrick Vallance, president of pharmaceuticals R&D at GSK, comments: “Cell based gene therapies are living treatments, unique to individual patients and complex to manufacture. We see tremendous potential for the cell and gene therapy platform we are building within GSK, however the complexity of current manufacturing processes limits their use to local treatment of small patient populations. Working with Miltenyi Biotec, our vision is to transform current technology so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach.”
Stefan Miltenyi, president and CEO of the German-based company, adds: “For more than 20 years we have been developing and providing cell therapy solutions to patients worldwide. Working together with the global experts at GSK, we will accelerate innovation to broaden patient access to future personalised cell and gene therapy.”
Sean Murray
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
